-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab Announces New And Updated Data From Three Arms Of Ongoing Phase 1b/2 EPCORE CLL-1 Trial Evaluating Efficacy And Safety Of Epcoritamab-Bysp For Treatment Of RT Patients

Benzinga·12/08/2025 21:34:49
Listen to the news
  • Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy
  • Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT
  • Results underscore the potential of epcoritamab as a versatile therapy for a broad range of B-cell malignancies

Genmab A/S (NASDAQ:GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter transformation (RT), a rare complication in which chronic lymphocytic leukemia (CLL) evolves into an aggressive lymphoma, most often diffuse large B-cell lymphoma (DLBCL). The results were presented today in two oral presentations (abstracts 1015 and 1017) at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida.